It is specifically contraindicated for individuals with: A personal or family history of medullary thyroid carcinoma (MTC), based on findings of thyroid C-cell tumours in animal studies Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Type 1 diabetes or diabetic ketoacidosis semaglutide is not designed for this purpose Pregnancy, or plans to become pregnant within the next 2 months (semaglutide should be discontinued at least 2 months before attempting conception) Age under 12 years (Wegovy is approved from age 12 only for severe obesity, under specialist supervision) Additional caution is needed for patients with a history of pancreatitis, gallbladder disease, diabetic retinopathy, or significant kidney impairment these patients require closer monitoring throughout treatment
Antioxidants (Basel, Switzerland), 8(4), 82
Monitor baseline and monthly IGF-1 levels to track GH response
They only correspond to a milligram dose when you know the exact concentration in the vial and the scale of the syringe
Its unclear, however, exactly when medications now being studied will win FDA approval
Agnihotri S, Burrell KE, Wolf A, Jalali S, Hawkins C, Rutka JT, et al